-
Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
NASDAQ: ALLR 1. Introduction to Allarity’s Early Phase 2 Stenoparib Data The field of oncology continues to witness groundbreaking advancements in precision medicine, with targeted therapies revolutionizing the treatment landscape for various cancers. In this context, Allarity, a leading biotechnology company, has recently released early phase 2 data showcasing the potential clinical benefit of their…
-
KALA BIO | Stock Price Up Today 43%+, Get Ready For A Move
NASDAQ: KALA Introduction to KALA BIO and its recent stock performance Investors and traders have been closely monitoring the recent surge in KALA BIO’s stock price, which has seen a remarkable 43% increase. KALA BIO, a pharmaceutical company focused on developing innovative therapies, has captured the attention of the market with its promising advancements. In…
-
NeuroSense | Reporting Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
NASDAQ: NRSN Introduction NeuroSense, a groundbreaking biopharmaceutical company, is set to release the highly anticipated topline results of its Phase 2b clinical trial for ALS (Amyotrophic Lateral Sclerosis) on December 5, 2023. This milestone event marks a significant step forward in the search for new treatment options for this devastating disease. In this article, we…
-
Soligenix | Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet’s Disease
NASDAQ: SNGX Introduction to Soligenix’s Phase 2 Clinical Trial Soligenix, a biopharmaceutical company focused on developing innovative therapies, has recently received FDA Investigational New Drug (IND) clearance for the Phase 2 clinical trial of Dusquetide in the treatment of aphthous ulcers in Behçets Disease. This clearance marks a significant milestone in the development of potential…
-
Biomea Fusion | Presenting New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
NASDAQ: BMEA BMF-219 is an investigational novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 2 diabetes STOCK & PRESS RELEASE INFO
-
BrainStorm Cell Therapeutics | Announces FDA Advisory Committee Meeting to Review NurOwn® PDUFA Target Action Date Scheduled for December 8, 2023
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced that the US FDA has granted the company a meeting to discuss the regulatory path forward for NurOwn® in ALS. The meeting, scheduled for December 6, 2023, will focus on plans for a Special Protocol Assessment (SPA) for a confirmatory Phase 3 trial in ALS. BrainStorm aims to…
-
Aptose Biosciences | Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
NASDAQ: APTO Aptose Biosciences Inc. announced that clinical data for tuspetinib has been selected for oral presentation at the 65th American Society of Hematology Annual Meeting. The presentation will include safety and efficacy data from Aptose’s ongoing APTIVATE trial of tuspetinib in relapsed/refractory acute myeloid leukemia patients. The presentation will take place on December 9,…
-
Rocket Pharmaceuticals | Unlocking the Potential: RP-L201 and its FDA Designations – A Breakthrough in Pediatric Medicine
NASDAQ: RCKT Rocket Pharmaceuticals has achieved significant milestones with their groundbreaking therapy, RP-L201. The FDA has granted several prestigious designations to RP-L201, including Regenerative Medicine Advanced Therapy (RMAT), Rare Pediatric, Fast Track, and Orphan Drug designations. These designations highlight the immense potential of RP-L201 in treating pediatric patients and emphasize the urgent need for innovative…
-
Aquestive Therapeutics | FDA Acceptance of Libervant™ for Treatment of Seizure Clusters in Young Patients
NASDAQ: AQST The FDA has recently accepted the New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film, aiming to tackle the treatment of seizure clusters in children between the ages of two and five. This development provides hope for young patients and their families who have pbeen struggling with the challenges of managing seizure clusters.…